Entospletinib
- Generic Name
- Entospletinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H21N7O
- CAS Number
- 1229208-44-9
- Unique Ingredient Identifier
- 6I3O3W6O3B
- Background
Entospletinib has been used in trials studying the treatment of Oncology, Follicular Lymphoma, B-cell Malignancies, Mantle Cell Lymphoma, and Non-Hodgkin Lymphoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
- Conditions
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Kronos Bio
- Target Recruit Count
- 15
- Registration Number
- NCT05020665
- Locations
- 🇺🇸
Mount Sinai Health System, New York, New York, United States
🇫🇷Hôpital Côte De Nacre, Caen, Calvados, France
🇺🇸Hollings Cancer Center, Charleston, South Carolina, United States
Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy
- Conditions
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 25
- Registration Number
- NCT03225924
- Locations
- 🇧🇪
UCL Namur, Yvoir, Belgium
🇧🇪Institut Jules Bordet, Bruxelles, Belgium
🇧🇪Az Groeninge, Kortrijk, Belgium
Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults
- Conditions
- Interventions
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 9
- Registration Number
- NCT03135028
- Locations
- 🇯🇵
University of Fukui Hospital, Fukui, Japan
🇯🇵Tokai University Hospital, Kanagawa, Japan
🇯🇵Tohoku University Hospital, Miyagi, Japan
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Alexey Danilov, MD
- Target Recruit Count
- 24
- Registration Number
- NCT03010358
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT02983617
- Locations
- 🇩🇪
Evangelisches Diakoniekrankenhaus Bremen Hämatologie, Bremen, Germany
🇩🇪Universitätsklinikum Heidelberg, Abteilung Innere Medizin V, Heidelberg, Germany
🇩🇪Uniklinik Köln Klinik I für Innere Medizin, Köln, Germany
Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 10
- Registration Number
- NCT02568683
- Locations
- 🇫🇷
Centre Hospitalier Régional Universitaire de Lille (CHRU de Lille), Lille cedex, NORD Pas-de-calais, France
🇫🇷Centre Hospitalier Universitaire de Dijon Hôpital du Bocage, Dijon Cedex, France
🇫🇷Groupe Hospitalier du Haut Leveque, Pessac, Aquitaine, France
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 56
- Registration Number
- NCT02521376
- Locations
- 🇺🇸
The Texas Liver Institute, San Antonio, Texas, United States
🇳🇿Auckland Clinical Studies, Auckland, New Zealand
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 203
- Registration Number
- NCT02457598
- Locations
- 🇬🇧
Cardiff and Vale Health Board, Clinical Research Facility, Cardiff, United Kingdom
🇺🇸Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Interventions
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT02404220
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸UCLA, Los Angeles, California, United States
🇩🇪Medizinische Klinik und Poliklinik I, Wurzburg, Germany
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 148
- Registration Number
- NCT02343939
- Locations
- 🇺🇸
University of Kansas Medical Center Research Institute, Inc, Fairway, Kansas, United States
🇩🇪Universitätsklinikum Frankfurt Medizinische Klinik II, Frankfurt, Germany
🇺🇸Weill Cornell Medical College - New York - Presbyterian Hospital, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.